Simultaneous modelling of flosequinan and its metabolite.

Design: A randomised, double-blind, prospective, placebo-controlled four-way study of the pharmacokinetics of single oral doses of flosequinan. We do not report the placebo data in this paper. Flosequinan was given at doses of 50, 100 and 150 mg, with a 2-week wash-out between periods.

Sibutramine pharmacokinetics in young and elderly healthy subjects.

Objective: To investigate the pharmacokinetics of the pharmacologically active metabolites of sibutramine (metabolites 1 and 2) in healthy young and elderly volunteers following a single oral dose of sibutramine.

Methods: This was an open, parallel-group study completed by 12 young (six male, six female; mean age 24.0 years) and 12 elderly (six male, six female; mean age 70.

Pharmacokinetics of flosequinan in patients with heart failure.

Objective: The pharmacokinetics of flosequinan were studied in a group of 18 patients with chronic cardiac failure.

Results: After a single dose of 100 mg, Cmax of the parent compound (2.52 mg.

Pharmacokinetics, safety, and tolerability of flosequinan in patients with hepatic dysfunction.

The pharmacokinetics of flosequinan and its active metabolite, flosequinoxan, were investigated following a single 100-mg oral dose in 10 patients with compromised hepatic function. Plasma and urine samples were collected for up to 144 h postdose and analyzed by HPLC. All 10 patients provided analyzable data even though one patient withdrew before the 144-h sample because of an adverse event unrelated to the study medication.

Effects of concurrent administration of flosequinan and digoxin on the pharmacokinetics of each drug.

The pharmacokinetic and pharmacodynamic effects of co-administration of flosequinan (BTS 49465, CAS 76568-02-0) and digoxin (CAS 20830-75-5) were investigated in 12 healthy volunteers. A 4-day, open, lead-in phase established the pharmacokinetics of flosequinan (100 mg on the first day and 50 mg for the next 3 days) and was followed by a 24-day open interaction phase. Digoxin was administered alone (0.

A multiple dose pharmacokinetic and tolerance study of once daily 200 mg sustained-release flurbiprofen capsules in young and very elderly patients.

The pharmacokinetic profile of 200 mg sustained-release flurbiprofen capsules was compared in nine elderly (mean age 84.2 years) and 10 young (mean age 38.1 years) patients with arthritis.

The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers.

The pharmacokinetic and haemodynamic effects of a 200 mg oral dose of BTS 49 465 (7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone) were investigated in a double-blind placebo controlled study. BTS 49 465 was rapidly absorbed and cleared from the systemic circulation with a half-life of 1.6 h by oxidation to the sulphone metabolite.

Pharmacokinetics of oral and rectal flurbiprofen in children.

Eight subjects, aged 6-12 years and weighing 18.8-36.7 kg, received single doses of flurbiprofen 50 or 75 mg (corresponding to 1.

The effect of flurbiprofen on the responses to frusemide in healthy volunteers.

Ten subjects participated in a four-way, open, crossover study to investigate the effect of frusemide, flurbiprofen, flurbiprofen plus frusemide, and placebo on urinary volume, sodium, and potassium. Compared with placebo, flurbiprofen was shown to significantly reduce all three parameters. The diuretic effect of frusemide was reduced by the addition of flurbiprofen but not to a statistically significant degree.